How One Drug Heavy-Lifted Biogen's Fourth-Quarter Beat

Biogen Leans Heavily Onto One Drug In Fourth-Quarter Beat | Investor's Business DailyBREAKING: [Dow Leads Stocks Higher As Nvidia, Goldman Sachs Rally]---Biogen (BIIB) narrowly topped Wall Street's fourth- quarter expectations Friday, thanks to far better-than-expected sales of multiple sclerosis treatment Tysabri. But Tysabri's victory lap could be short-lived. In November, Sandoz launched its generic version of the multiple sclerosis drug in the U.S. Biosimilars have existed in Europe for years and Tysabr ...